1.
Survival analysis of intraoperative blood salvage for patients with malignancy disease: A PRISMA-compliant systematic review and meta-analysis
Wu WW, Zhang WY, Zhang WH, Yang L, Deng XQ, Ou MC, Yang YX, Liu HB, Zhu T
Medicine. 2019;98(27):e16040
Abstract
BACKGROUND Intraoperative blood salvage as a blood-saving strategy has been widely used in surgery. Considering its theoretic risk of malignant tumor cells being reinfused and the corresponding blood metastases, the safety of intraoperative blood salvage in cancer surgery remains controversial. METHODS Following the Preferred Reporting Items for Systemic Review and Meta-Analysis (PRISMA), we searched the Cochrane Library, MEDLINE and EMBASE to November 2017. We included only studies comparing intraoperative blood salvage with allogeneic blood transfusion. RESULTS This meta-analysis included 9 studies with 4354 patients with 1346 patients in the intraoperative blood salvage group and 3008 patients in the allogeneic blood transfusion group. There were no significant differences in the 5-year overall survival outcome (odds ratio [OR] 1.12; 95% confidence interval [CI], 0.80-1.58), 5-year disease-free survival outcome (OR 1.08; 95% CI 0.86-1.35), or 5-year recurrence rate (OR 0.86; 95% CI 0.71-1.05) between the 2 study groups. Subgroup analysis also showed no significant differences in the 5-year overall survival outcome (OR 0.97; 95% CI 0.57-1.67) of hepatocellular carcinoma patients in liver transplantation. CONCLUSIONS For patients with malignant disease, intraoperative blood salvage did not increase the tumor recurrence rate and had comparable survival outcomes with allogeneic blood transfusion.
2.
Influence of perioperative leukodeplated red blood cell transfusion on immune function of patients with bladder cancer
Shi J, Gao B, Yang Y, Yang L, Li X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology. 2018;34((7)):632-636.
Abstract
Objective To investigate the effect of leukodeplated red blood cell (RBC) transfusion on immune function of patients with bladder cancer. Methods A total of 48 patients with bladder cancer who required perioperative RBC transfusion were randomized into two groups: 22 received leukodeplated RBC transfusion (Group I) and 26 received suspended RBC transfusion (Group II ). T-cell subgroup, natural killer cell activity, erythrocyte-C3b receptor rosette formation rate, and immunosuppressive acidic protein (IAP) level were determined for the two groups before and after transfusion, and the results were statistically analyzed. Results There was no obvious difference in immune function between the two groups before transfusion. After transfusion, the immune function of both groups was lower. However, it was higher in Group I than in Group II . IAP level was higher after transfusion than before transfusion; however, it was lower in Group I than in Group II . Conclusion Perioperative RBC transfusion can decrease immune function in patients with bladder cancer. Compared with suspended RBC transfusion, leukodeplated RBC transfusion can improve immune function in patients with bladder cancer.